Reuters logo
a month ago
BRIEF-Matinas Biopharma reports topline data from phase 2 clinical study of vaginal drug
June 26, 2017 / 10:20 AM / a month ago

BRIEF-Matinas Biopharma reports topline data from phase 2 clinical study of vaginal drug

1 Min Read

June 26 (Reuters) - Matinas Biopharma Holdings Inc:

* Matinas Biopharma reports topline data from phase 2 clinical study of orally-administered mat2203 for the treatment of vulvovaginal candidiasis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below